Table 1 Basic characteristics of trials included in the present study
Author | Publication years | Country | Chemotherapy regimens | Chemotherapy group (number of death/total) | Surgery group (number of death/total) | Follow-uptime (months) | Chemotherapy group (number of R0/total) | Surgery group (number of R0/total) | Peritoneal recurrence in chemotherapy group | Peritoneal recurrence in surgery group | |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Koga S[16] | 1988 | Japan | 8-10 μg/ml MMC, 8-12 L, 50-60 min, 44-45°C | 4/26 | 7/21 | 30 | 26/26 | 21/21 | NA | NA |
2 | Hamazoe R[17] | 1993 | Japan | 10 μg/ml MMC, 10-12 L, 50-60 min, 48-50°C | 18/42 | 22/40 | 77 | 40/42 | 35/40 | 7* | 13* |
3 | Fujimura T[18] | 1994 | Japan | 30 mg MMC + 300 mg CDDP, 6-8 L,60 min, 41-42°C | 7/22 | 14/18 | 36 | NA | NA | 2* | 4* |
4 | Ikeguchi M[19] | 1995 | Japan | 8-10 μg/ml MMC, 8-10 L, 50-60 min, 44-45°C | 38/78 | 52/96 | 60 | 78/78 | 96/96 | 27* | 38* |
5 | Fujimoto S[20] | 1998 | Japan | 10 μg/ml MMC, 3-4 L, 120 min, 44.5-45°C | 27/71 | 36/70 | 96 | 67/71 | 65/70 | 1* | 16* |
6 | Yonemura Y[21] | 2001 | Japan | 30 mgMMC + 300 mg CDDP, 6-8 L, 60 min, 42-43°C | 19/48 | 27/47 | 60 | 48/48 | 47/47 | 6 | 7 |
7 | Zuo Y[22] | 2004 | China | 80-100 mg CDDP + 1000 mg 5-FU + 5 mg, 2 L,60 min, 41–43°C | 8/46 | 14/36 | 36 | NA | NA | NA | NA |
8 | Wei G[23] | 2005 | China | 1000 μg/ml 5-UF, 4-5 L, 60 min, 43-45°C | 21/42 | 25/46 | 36 | 40/49 | 49/55 | NA | NA |
9 | Zhang GY[24] | 2007 | China | 30 mg MMC + 300 mg CDDP, 2 L, 30 min, 42-45°C | 44/92 | 75/120 | 60 | 92/92 | 120/120 | 13 | 45 |
10 | Deng HJ[25] | 2009 | China | 300-500 μg/ml 5-FU, 3 L, 60-90 min, 42-43°C | 18/44 | 27/41 | 60 | 44/44 | 41/41 | NA | NA |